Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications
Herzschrittmachertherapie + Elektrophysiologie · 2023
DOI: 10.1007/s00399-023-00944-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Herzschrittmachertherapie + Elektrophysiologie, 2023. Verfasst von Andreas Goette und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik II: Kardiologie und Intensivmedizin, St. Vincenz-Krankenhaus Paderborn, Am Busdorf 2, 33098, Paderborn, Germany. andreas.goette@v…. Hauptthemen laut MEDLINE: Anticoagulants, Atherosclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-vitamin K antagonist oral anticoagulants (NOACs) are well-established as inhibitors of factor Xa (FXa) and thrombin in the treatment and prevention of thrombosis. However, there is growing evidence that beneficial outcomes might be based on additional pleiotropic effects beyond anticoagulation. FXa and thrombin are also known to activate protease-activated receptors (PARs), which can mediate pro-inflammatory and pro-fibrotic effects. Since PAR‑1 and PAR‑2 play an important role in the development of atherosclerosis, the inhibition of this pathway represents an interesting potential target for preventing the progression of atherosclerosis and fibrosis. This review focuses on potential pleiotropic effects of FXa inhibition with edoxaban seen in a variety of studies in different in vitro and in vivo test systems. As common findings from these experiments, edoxaban was able to attenuate FXa- and thrombin-induced pro-inflammatory and pro-fibrotic effects and decrease pro-inflammatory cytokine expression. In some, but not all experiments edoxaban was also shown to decrease the levels of PAR‑1 and PAR‑2 expression. Further studies are required to clarify the clinical implications of the pleiotropic effects mediated by NOACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medizinische Klinik II: Kardiologie und Intensivmedizin, St. Vincenz-Krankenhaus Paderborn, Am Busdorf 2, 33098, Paderborn, Germany. andreas.goette@vincenz.de.
- Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
- Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bochum, Germany.
- Daiichi Sankyo Europe GmbH, Munich, Germany.
- Daiichi Sankyo Deutschland GmbH, Munich, Germany.
Zitieren
APA
Goette, A., Mollenhauer, M., Rudolph, V., Lamparter, M., Meier, M., & Böhm, M. (2023). Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications. Herzschrittmachertherapie + Elektrophysiologie. https://doi.org/10.1007/s00399-023-00944-5
Vancouver
Goette A, Mollenhauer M, Rudolph V, Lamparter M, Meier M, Böhm M. Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications. Herzschrittmachertherapie + Elektrophysiologie. 2023. doi:10.1007/s00399-023-00944-5
BibTeX
@article{Goette2023,
author = {Goette, Andreas and Mollenhauer, Martin and Rudolph, Volker and Lamparter, Mathias and Meier, Martin and Böhm, Michael},
title = {Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications},
journal = {Herzschrittmachertherapie + Elektrophysiologie},
year = {2023},
doi = {10.1007/s00399-023-00944-5}
}
EUVIMED